Literature DB >> 19609591

Melanoma complicating treatment with natalizumab (tysabri) for multiple sclerosis.

Azza Ismail, Julie Kemp, Basil Sharrack.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19609591     DOI： 10.1007/s00415-009-5200-9

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  14 in total

1.  Natalizumab and progressive multifocal leukoencephalopathy.

Authors:  Burt Adelman; Alfred Sandrock; Michael A Panzara
Journal:  N Engl J Med       Date:  2005-06-09       Impact factor: 91.245

2.  Melanoma complicating treatment with natalizumab for multiple sclerosis.

Authors:  John T Mullen; Timothy K Vartanian; Michael B Atkins
Journal:  N Engl J Med       Date:  2008-02-07       Impact factor: 91.245

3.  Transcriptional regulation of the alpha 4 integrin subunit gene in the metastatic spread of uveal melanoma.

Authors:  N Larouche; K Larouche; A Béliveau; S Leclerc; C Salesse; G Pelletier; S L Guérin
Journal:  Anticancer Res       Date:  1998 Sep-Oct       Impact factor: 2.480

4.  Enhanced induction of very late antigen 4/lymphocyte function-associated antigen 1-dependent T-cell migration to tumor sites following administration of interleukin 12.

Authors:  M Ogawa; T Tsutsui; J P Zou; J Mu; R Wijesuriya; W G Yu; S Herrmann; T Kubo; H Fujiwara; T Hamaoka
Journal:  Cancer Res       Date:  1997-06-01       Impact factor: 12.701

5.  Expression of the integrin alpha 4 beta 1 on melanoma cells can inhibit the invasive stage of metastasis formation.

Authors:  F Qian; D L Vaux; I L Weissman
Journal:  Cell       Date:  1994-05-06       Impact factor: 41.582

6.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

Authors:  Richard A Rudick; William H Stuart; Peter A Calabresi; Christian Confavreux; Steven L Galetta; Ernst-Wilhelm Radue; Fred D Lublin; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

7.  Regulation of integrin activity by MIA.

Authors:  Richard Bauer; Martin Humphries; Reinhard Fässler; Andreas Winklmeier; Sue E Craig; Anja-Katrin Bosserhoff
Journal:  J Biol Chem       Date:  2006-03-03       Impact factor: 5.157

Review 8.  Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients.

Authors:  Claas Ulrich; Tobias Schmook; Michael M Sachse; Wolfram Sterry; Eggert Stockfleth
Journal:  Dermatol Surg       Date:  2004-04       Impact factor: 3.398

Review 9.  Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases?

Authors:  Richard J Davenport; James R Munday
Journal:  Drug Discov Today       Date:  2007-06-26       Impact factor: 7.851

10.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

Authors:  Chris H Polman; Paul W O'Connor; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; David H Miller; J Theodore Phillips; Fred D Lublin; Gavin Giovannoni; Andrzej Wajgt; Martin Toal; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245
View more
  11 in total

Review 1.  Natalizumab (Tysabri).

Authors:  D T Selewski; G V Shah; B M Segal; P A Rajdev; S K Mukherji
Journal:  AJNR Am J Neuroradiol       Date:  2010-08-05       Impact factor: 3.825

Review 2.  [Therapeutic monoclonal antibodies in clinical neurology].

Authors:  M Buttmann; H Wiendl
Journal:  Nervenarzt       Date:  2010-06       Impact factor: 1.214

3.  Association of melanoma and natalizumab therapy in the Italian MS population: a second case report.

Authors:  A Laroni; M Bedognetti; A Uccelli; E Capello; G L Mancardi
Journal:  Neurol Sci       Date:  2010-11-05       Impact factor: 3.307

Review 4.  Immunogenicity and other problems associated with the use of biopharmaceuticals.

Authors:  Michael G Tovey; Christophe Lallemand
Journal:  Ther Adv Drug Saf       Date:  2011-06

Review 5.  Requirement for safety monitoring for approved multiple sclerosis therapies: an overview.

Authors:  P S Rommer; U K Zettl; B Kieseier; H-P Hartung; T Menge; E Frohman; B M Greenberg; B Hemmer; O Stüve
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

Review 6.  Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities.

Authors:  Justin M Honce; Lidia Nagae; Eric Nyberg
Journal:  Mult Scler Int       Date:  2015-09-21

Review 7.  Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR).

Authors:  Rachel A Sabol; Virginia Noxon; Oliver Sartor; Joseph R Berger; Zaina Qureshi; Dennis W Raisch; LeAnn B Norris; Paul R Yarnold; Peter Georgantopoulos; William J Hrushesky; Laura Bobolts; Paul Ray; Akida Lebby; Robert C Kane; Charles L Bennett
Journal:  Cancer Med       Date:  2017-06-20       Impact factor: 4.452

8.  Recent developments in multiple sclerosis therapeutics.

Authors:  Rebecca I Spain; Michelle H Cameron; Dennis Bourdette
Journal:  BMC Med       Date:  2009-12-07       Impact factor: 8.775

Review 9.  Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life.

Authors:  Raquel Planas; Roland Martin; Mireia Sospedra
Journal:  Patient Relat Outcome Meas       Date:  2014-04-04

10.  Multiple Sclerosis Treatment and Melanoma Development.

Authors:  Maria Luigia Carbone; Pedro Miguel Lacal; Serena Messinese; Laura De Giglio; Carlo Pozzilli; Severino Persechino; Cinzia Mazzanti; Cristina Maria Failla; Gianluca Pagnanelli
Journal:  Int J Mol Sci       Date:  2020-04-22       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.